Abstract
We conducted a test-negative case-control study based in five European sentinel surveillance networks. The early 2012/13 adjusted influenza vaccine effectiveness was 78.2% (95% CI: 18.0 to 94.2) against influenza B, 62.1% (95% CI: -22.9 to 88.3%) against A(H1) pdm09, 41.9 (95% CI: -67.1 to 79.8) against A(H3N2) and 50.4% (95% CI: -20.7 to 79.6) against all influenza types in the target groups for vaccination. Efforts to improve influenza vaccines should continue to better protect those at risk of severe illness or complications.
Publication types
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Case-Control Studies
-
Child
-
Child, Preschool
-
Disease Outbreaks / prevention & control*
-
Disease Outbreaks / statistics & numerical data
-
Europe / epidemiology
-
Female
-
Humans
-
Infant
-
Infant, Newborn
-
Influenza A Virus, H1N1 Subtype / immunology*
-
Influenza A Virus, H1N1 Subtype / isolation & purification
-
Influenza A Virus, H3N2 Subtype / immunology*
-
Influenza A Virus, H3N2 Subtype / isolation & purification
-
Influenza B virus / immunology*
-
Influenza B virus / isolation & purification
-
Influenza Vaccines / administration & dosage*
-
Influenza Vaccines / immunology
-
Influenza, Human / epidemiology
-
Influenza, Human / prevention & control*
-
Influenza, Human / virology
-
Male
-
Middle Aged
-
Seasons
-
Sentinel Surveillance
-
Treatment Outcome
-
Vaccination / statistics & numerical data*
-
Young Adult